Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The pancreatic beta cell’s insulin secretion pathway integrates metabolic sensing with electrical activity and exocytic machinery—primarily through a cascade initiated by increased intracellular ATP following glycolysis—which ultimately results in tightly controlled pulsatile release of insulin into circulation for systemic glycemic regulation. It involves glucose uptake via GLUT transporters, glycolysis leading to increased ATP/ADP ratio, KATP channel closure causing membrane depolarization, calcium influx through VDCCs, and exocytosis of insulin granules. This pathway is crucial for maintaining blood glucose homeostasis and is dysregulated in diabetes.
Varies depending on the specific target within the pathway. Sulfonylureas close KATP channels. GLP-1 receptor agonists increase cAMP and activate PKA and Epac2 pathways.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Insulin Secretion Pathway (Pancreatic Beta Cell).